Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial

OBJECTIVES: To evaluate the 1-year efficacy and safety of once-monthly erenumab 70 mg following a 24-week double-blind treatment period (DBTP) of a phase III randomised study of Japanese patients with episodic migraine (EM) or chronic migraine (CM). DESIGN: Multicentre open-label study. SETTING: A t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirata, Koichi, Takeshima, Takao, Sakai, Fumihiko, Numachi, Yotaro, Yoshida, Ryuji, Koukakis, Reija, Hasebe, Miki, Yui, Daishi, da Silva Lima, Gabriel Paiva, Cheng, Sunfa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441051/
https://www.ncbi.nlm.nih.gov/pubmed/37597868
http://dx.doi.org/10.1136/bmjopen-2022-068616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441051/
https://www.ncbi.nlm.nih.gov/pubmed/37597868
http://dx.doi.org/10.1136/bmjopen-2022-068616

Ejemplares similares